Quantum BioPharma

Newron Pharmaceuticals Advances Pivotal Phase III Program for Treatment-Resistant Schizophrenia

2 months ago

• Newron Pharmaceuticals has received regulatory approval for its ENIGMA-TRS Phase III program evaluating Evenamide as an add-on therapy for treatment-resistant schizophrenia, with patient recruitment beginning immediately. • The pivotal program consists of two studies designed to meet requirements for marketing authorization in major markets including the USA and Europe, with results expected by late 2026. • Evenamide, a first-in-class glutamate modulator, has shown promising results in earlier trials with 70% of TRS patients experiencing clinically significant benefits and 25% achieving remission during one-year treatment.

Quantum BioPharma's UnbuzzdTM Shows 40% Faster Alcohol Metabolism in Clinical Trial

4 months ago

• Clinical trial demonstrates UnbuzzdTM dietary supplement accelerates alcohol metabolism by 40% within 30 minutes compared to placebo, while improving alertness and stabilizing vital signs. • Study participants reported reduced mental fatigue and hangover symptoms without experiencing adverse side effects, marking a significant advancement in alcohol consumption management. • Quantum BioPharma maintains pharmaceutical development rights while partnering with Celly Nutrition for over-the-counter distribution, securing ongoing royalties up to $250 million.

Clearmind Medicine's CMND-100 Receives IRB Approval for AUD Clinical Trial at Yale

5 months ago

• Clearmind Medicine received IRB approval for its Phase I/IIa clinical trial of CMND-100, a novel therapeutic targeting alcohol use disorder (AUD). • The trial, to be conducted at Yale School of Medicine, will assess the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings. • CMND-100 aims to address the critical gap in AUD treatment, where current options have limited efficacy (less than 30%) and patient compliance. • Alcohol consumption causes 2.6 million deaths annually worldwide, highlighting the urgent need for effective AUD treatments.

Quantum BioPharma Advances Lucid-21-302 Clinical Trial for Multiple Sclerosis

5 months ago

• Quantum BioPharma's Lucid-21-302, a potential treatment for multiple sclerosis, has progressed to the second cohort dosing phase after positive safety review. • The Phase 1 trial evaluates the safety and pharmacokinetics of Lucid-21-302 in healthy adults, with dosing for the next group expected to begin shortly. • Quantum BioPharma's subsidiary, Lucid Psycheceuticals Inc., focuses on developing Lucid-MS to prevent and reverse myelin degradation in multiple sclerosis. • The company maintains a healthy current ratio of 3.76, indicating a strong ability to meet short-term obligations, and holds significant tax loss carry forwards.

Phase 1 Trial of Lucid-MS Initiated to Protect Myelin Sheath in Multiple Sclerosis

7 months ago

• Quantum Biopharma's Lucid-21-302, a potential oral treatment for multiple sclerosis (MS), has entered a Phase 1 safety and tolerability trial in healthy adults. • The trial aims to assess the safety and pharmacological profile of Lucid-MS, with findings expected to inform the design of a Phase 2 clinical trial in MS patients. • Lucid-MS is designed to protect and potentially repair the myelin sheath, which is damaged in MS, without suppressing the immune system. • Preclinical studies in animal models of MS showed that Lucid-MS restored mobility following paralysis, suggesting potential for functional recovery.